Results · Apr-Jun 2026
Indo US Bio-Tech Q1 FY27 results
Sales grew 7% to ₹33 crore from ₹30.8 crore in Apr-Jun 2025.
Operating profit fell 28% to ₹4 crore, an operating margin of 12.0% (down 5.8 points from a year ago).
Net profit fell 35% to ₹3 crore from ₹4.7 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +27%, net profit +54%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 33.0 | 30.8 | +7% |
| Operating profit (EBITDA) | 4.0 | 5.5 | −28% |
| Operating margin | 12.0% | 17.8% | −5.8 pts |
| Net profit | 3.0 | 4.7 | −35% |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.